|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61K 9/16 | (2006.01) |
| A61K 9/1647 | (2013.01) | ||
| A61K 9/00 | (2006.01) | ||
| A61K 9/1629 | (2013.01) | ||
| A61K 47/34 | (2017.01) | ||
| A61P 25/00 | (2018.01) | ||
| A61K 31/551 | (2006.01) | ||
| A61K 31/551 | (2013.01) | ||
| A61P 25/18 | (2006.01) | ||
| A61K 9/0019 | (2013.01) | ||
| A61P 25/00 | (2006.01) | ||
| A61K 31/00 | (2013.01) |
| (11) | Patento numeris | 3352735 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 16775424.1 |
| Europos patento paraiškos padavimo data | 2016-09-21 | |
| (97) | Europos patento paraiškos paskelbimo data | 2018-08-01 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2023-08-30 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/US2016/052757 |
| Data | 2016-09-21 |
| (87) | Numeris | WO 2017/053346 |
| Data | 2017-03-30 |
| (30) | Numeris | Data | Šalis |
| 201562221290 P | 2015-09-21 | US |
| (72) |
SMITH, Mark, Alan , US
CLAASSEN-PUNT, Carine , NL
|
| (73) |
Teva Pharmaceuticals International GmbH ,
Schlüsselstrasse 12, 8645 Jona,
CH
|
| (54) | SUSTAINED RELEASE OLANZAPINE FORMULATIONS |
| SUSTAINED RELEASE OLANZAPINE FORMULATIONS |